A study to compare rates of acute liver injury with Protease inhibitors versus non-protease inhibitor based direct-acting antivirals for HCV-infected initiators
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Paritaprevir/ritonavir (Primary) ; Ledipasvir/sofosbuvir; Sofosbuvir/velpatasvir
- Indications Hepatitis C
- Focus Adverse reactions
- 10 Dec 2020 New trial record